Cyprumed's Oral Peptide Tablet Technology Enters Human Clinical Development As MSD Initiates Phase I Trial, Triggering Milestone Payment For Up To $493M From MSD
The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical developmentThe milestone
Cyprumed's pill technology is starting human testing with help from MSD. MSD might pay Cyprumed up to $493 million if the drug works out.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.